Founded in 2008, MyndTec is focused on commercializing innovative medical technologies through the company’s extensive business, innovation and intellectual property expertise and through its work with leading global partners. MyndTec has developed rehabilitative therapies for upper body paralysis in stroke and spinal cord injury (SCI) patients and has received regulatory clearance for its MyndMove™ and MyndStep™ products in the U.S. and Canada. Working to overcome the challenges faced by early stage medtech companies, MyndTec has identified market needs and opportunities for new and innovative medical therapies, which it seeks to build upon through acquisition, licensing, research and development, and intellectual property expansion.
In 2022, MyndTec listed its common shares on the Canadian Securities Exchange (CSE) to allow the company the opportunity to attract additional investors, scale its business, and identify synergistic opportunities in delivering innovative medical technologies. The company’s common shares are listed under the ticker MYTC on the CSE.
At MyndTec our mission is to improve the quality of human life by enabling people to do more, feel better and live independently, through innovation and utilization of technology and cost-effective access to care
At MyndTec we want to celebrate your successes and help you achieve your best outcome, faster. Here are some success stories of what is possible.
See Our Success Stories